ecancer
@ecancer
Followers
17K
Following
6K
Media
5K
Statuses
22K
ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education. #openaccess
England
Joined February 2009
🔶 Live from #ESMO25 @OncoAlert @MedicalwatchHQ LAG-3 Expression & IO Response in mRCC 👩⚕️ Speaker: Rana R. McKay, MD (@DrRanaMcKay) 💡 Key insights: ➡️ LAG3 gene expression (RNA-NGS, n=425; Tempus database) positively correlated with CTLA4, PD-L1, TIM3, and TIGIT. ➡️ Higher
0
6
10
🔵 2594MO – KIM-1 & outcomes in aRCC (COSMIC-313) Live from #ESMO25 @OncoAlert @MedicalwatchHQ
@DrChoueiri @MyriamChalabi @myESMO 👩⚕️ Speaker: @VincentWenxinXu (Boston, USA) 💡 Key insights: ➡️ High baseline KIM-1 linked to worse IMDC risk, no prior nephrectomy, and higher tumor
0
12
17
Amazing results on Belzutifan in #pheochromocytoma #paraganglioma led by Camilo Jimenez + authors @JaydiDelRivero @Ja_Capdevila @GCarboneroLab mPFS 22 mo Overall disease control rate 85% Median time to response 11 mo Median duration response 20mo #ESMO25 #NEJM
0
15
29
📢 Breaking News Straight from #ESMO25! 🚀The innovative Phase 1b DeLLphi-303 trial is showing promising results in the treatment landscape for ES-SCLC! Encouraging results with Tarlatamab combined with 1L chemo-immunotherapy (chemo-IO) and anti-PD-L1 maintenance therapy. 📊
0
1
4
Impressive results from MDT-BRIDGE at #ESMO25 from Dr. @MartinReck2. Pts with resectable or borderline had 2 cycles of durvalumab + chemo then reassessed at MDT. If resectable at start, 95% remained resectable. If borderline, 82% were then felt to be resectable. #ESMOAmbassadors
2
36
78
The London Global Cancer Week Programme is live! 5 days of collaboration, knowledge & action to improve cancer outcomes. Explore sessions, speakers & institutions shaping global health → https://t.co/SxWklGocJz
#LGCW2025 #LondonGlobalCancerWeek #GlobalHealth #Cancer
0
3
1
ecancer is live-streaming from #EMUC25 in November: Latest strategies, innovations, and future directions in HR-NMIBC care from J&J's satellite symposium. Register for free here 👉 https://t.co/zWMER9HpQW
#bladdercancer @LAUrology_NL @evanguelosx @UroMoschini #oncology
0
0
1
🏨Bridging innovation and access, EAPM’s Berlin Edition focuses on equity in diagnostics, data & reimbursement for every patient. Join us during #ESMO to move from declarations to delivery. 🗓 Oct 17–18. 🔗 Register now: https://t.co/i2tnRnuRCS
#EAPMBerlin #oncology
0
1
1
Thrilled to win the FICCI excellence in healthcare awards, @ficci_india 2025 in delivery of patient care - a proud moment for @BalcoMedical @AnilAgarwalFndn - one of the most coveted awards- inspires us to do even better in what we do. So proud of the amazing team at BMC who
21
8
54
Congratulations to former CSO Fellow Dr. Omar Abdihamid (first author) and collaborators for publishing a paper in the European Journal of Cancer evaluating 55 randomized clinical trials for adherence to the CSO’s principles for phase III cancer RCTs published earlier this year
0
6
19
🇪🇸 A group of investigators from Valencia presents their 10-year experience with single-fraction lung SBRT at #ASTRO25. Their data reports 99% in-field local control with a median f/u time of 5 years. https://t.co/4ZBGA56A9H
1
24
48
🧠 Our new review: CAR-T in relapsed/refractory high-grade glioma & GBM 🔹 Early promise even in immune-protected CNS 🔹 Targets: B7-H3, GD2, IL-13Ra2, HER2, EGFRvIII 🔹 Patient selection & antigen profiling key 🔹 Phase II/III trials needed 👉
ecancer.org
CAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how? Deevyashali Parekh1, Ansy H Patel1, Areeb Khan1, Eloho Olojakpok
3
2
9
0
1
2
What an amazing feat the @BalcoMedical team pulled off .. meeting attended by >1000 with almost 200 from india, 12 globally from australia, NZ, UK, USA, Lebanon, Switzerland, singapore. key tracks were mini Accord research workshop, communication skills with role play to train
4
14
46
📅 15 Sept was #WorldLymphomaAwarenessDay ~735,000 people are diagnosed with lymphoma every year. Access to diagnostics & innovative therapies remains unequal. At ecancer, we amplify knowledge for better global outcomes. 👉 https://t.co/uJQSBEUiXf
#Leukaemia #Lymphoma
ecancer.org
Should we perform baseline NGS testing in precursor T lymphoblastic leukaemias: a single centre experience from Eastern India Prateek Das1,2, Sujeet Kumar2
0
0
0
Long-term outcomes from India support active surveillance as a safe option for stage I seminoma in a resource-constrained setting! https://t.co/kCtDawi6A9
@DrAmitJoshi_TMC @urotoday @oncodaily @ecancer @OncoAlert @Uroweb
ecancer.org
Is active surveillance a good treatment option for stage 1 seminoma in a developing nation? Long-term outcomes from the Indian subcontinent Aditya Dhanawat
2
4
7
🌸 September is #GynecologicCancerAwarenessMonth. Cervical, ovarian, uterine & vulvar cancers affect millions of women globally—yet screening & treatment remain unequal. 📖 https://t.co/PyW9lzYodJ #GynCancerAwareness #WomensHealth #EducationSavesLives
ecancer.org
Exploring women’s knowledge and their perception of risk of uterine cancer in Lagos, Nigeria: a multi-facility based cross-sectional study Adeyemi Adebola
0
0
1
Last and the best session - communications skills- how to communicate prognosis to our patients.. . Blown away by the planning that went into this session by the experts ! Shows in the execution of role plays and the talks.. Learnt so much. @BalcoMedical @ecancer @csoncol @ASCO
1
5
20
Pleasure to have @DrRiyazShah @docrohatgi drive the @ecancer @BalcoMedical @csoncol session on lung cancer , @cmcvelloreoff dr ashish singh ! Engaging discussions @y2k2011
0
3
11